-
公开(公告)号：EP3505162A1
公开(公告)日：2019-07-03
申请号：EP18197869.3
申请日：2011-08-11
申请人： Euro-Celtique S.A.
发明人： PRATER, Derek Allan , SPITZLEY, Christof , HEUN, Gerhard Josef , SCHÜTZ, Alexander , HAHN, Udo , LEUNER, Christian
IPC分类号： A61K9/20 , A61K31/485
摘要： The present invention relates to storage stable prolonged release pharmaceutical dosage forms comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof, the manufacture thereof as well as their use for administration to human beings.
-
2.发明授权
公开(公告)号：EP1492506B1
公开(公告)日：2008-12-31
申请号：EP03720425.2
申请日：2003-04-04
申请人： EURO-CELTIQUE S.A.
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/70 , Y10S514/81 , Y10S514/812
摘要： The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
-
公开(公告)号：EP3326618A1
公开(公告)日：2018-05-30
申请号：EP17169621.4
申请日：2003-04-04
申请人： Euro-Celtique S.A. , Mundipharma Medical CEE GmbH , Mundipharma GmbH , Mundipharma Medical Company Hamilton, Bermuda, Basel Branch , Mundipharma Pharmaceuticals S.L. , Mundipharma Pharmaceuticals S.r.l , Mundipharma SAS
IPC分类号： A61K9/20
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/70 , Y10S514/81 , Y10S514/812
摘要： The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.
-
4.发明授权MATRIX FOR SUSTAINED, INVARIANT AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS 有权MATRIXFÜRDIE MODIFIZIERTE FREIGABE VON AKTIVEN SUBSTANZEN
公开(公告)号：EP1492506B2
公开(公告)日：2016-06-29
申请号：EP03720425.2
申请日：2003-04-04
申请人： EURO-CELTIQUE S.A.
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/70 , Y10S514/81 , Y10S514/812
摘要： The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
摘要翻译： 本发明涉及一种储存稳定的药物制剂，其优选地包含在非溶胀性扩散基质中的两种活性化合物，其中化合物以持续的不变的方式从基质中释放，并且如果存在多种化合物，则是独立的方式，并且用 相对于其基本的释放特性由乙基纤维素和至少一种脂肪醇。 本发明还涉及生产这种药物制剂的方法。
-
公开(公告)号：EP2603205A2
公开(公告)日：2013-06-19
申请号：EP11743537.0
申请日：2011-08-11
申请人： Euro-Celtique S.A.
发明人： PRATER, Derek Allan , SPITZLEY, Christof , HEUN, Gerhard Josef , SCHÜTZ, Alexander , HAHN, Udo , LEUNER, Christian
IPC分类号： A61K9/20 , A61K31/485
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K2300/00
摘要： The present invention relates to storage stable prolonged release pharmaceutical dosage forms comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof, the manufacture thereof as well as their use for administration to human beings.
摘要翻译： 本发明涉及储存稳定的延长释放药物剂型包含羟考酮或其药学上可接受的盐和纳洛酮或其可药用盐，其制造以及其用于施用于人类。
-
公开(公告)号：EP1121109B8
公开(公告)日：2006-07-19
申请号：EP99953856.4
申请日：1999-10-15
申请人： EURO-CELTIQUE S.A.
IPC分类号： A61K31/135 , A61K9/20 , A61P25/04 , A61K9/52
CPC分类号： A61K31/485 , A61K9/209 , A61K31/135
摘要： The invention relates to a pharmaceutical preparation, especially for oral administration, having at least one active substance and formulation components influencing the release of the active substance. Said preparation comprises at least one opioid analgesic as active substance, which is formulated proportionally for rapid and retarded release in such a way that the in vitro release rate from the preparation according to the Ph. Eur. Paddle Method showed a mean value of more than 40 % by weight after one hour, wherein the average value of the in vitro release rate after four hours was still less than 80 % by weight of the active substance.
摘要翻译： 本发明涉及一种尤其用于口服给药的药物制剂，其具有至少一种活性物质和影响活性物质释放的制剂组分。 所述制剂包含至少一种阿片样物质止痛剂作为活性物质，其按比例配制用于快速和延迟释放，使得根据Ph.Eur。的制剂的体外释放速率 桨法在1小时后表现出超过40重量％的平均值，其中4小时后的体外释放速率的平均值仍小于活性物质的80重量％。
-
公开(公告)号：EP1492505A2
公开(公告)日：2005-01-05
申请号：EP03720424.5
申请日：2003-04-04
申请人： Euro-Celtique S.A.
IPC分类号： A61K9/16 , A61K9/20 , A61K9/22 , A61K31/485
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/70 , Y10S514/81 , Y10S514/812
摘要： The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
-
公开(公告)号：EP2603205B1
公开(公告)日：2018-10-03
申请号：EP11743537.0
申请日：2011-08-11
申请人： EURO-CELTIQUE S.A.
发明人： PRATER, Derek Allan , SPITZLEY, Christof , HEUN, Gerhard Josef , SCHÜTZ, Alexander , HAHN, Udo , LEUNER, Christian
IPC分类号： A61K9/20 , A61K31/485
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K2300/00
摘要： The present invention relates to storage stable prolonged release pharmaceutical dosage forms comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof, the manufacture thereof as well as their use for administration to human beings.
-
公开(公告)号：EP3228308A1
公开(公告)日：2017-10-11
申请号：EP17154428.1
申请日：2006-01-27
申请人： Euro-Celtique S.A.
发明人： MANNION, Richard Owen , MCKENNA, William, H. , O'DONNELL, Edward, P. , DANAGHER, Helen, Kathleen , HAYES, Geoffrey, Gerard , MOHAMMAD, Hassan , PRATER, Derek Allan , TAMBER, Harjit , WALDEN, Malcolm , WHITELOCK, Steve , FLEISCHER, Wolfgang , HAHN, Udo , SPITZLEY, Christof , LEUNER, Christian
CPC分类号： A61K9/1652 , A61K9/16 , A61K9/20 , A61K9/2054 , A61K9/2077 , A61K31/485 , A61K45/06
摘要： Opioid controlled release formulations resistant to alcohol extraction of the opioid.
摘要翻译： 阿片样物质控制释放制剂耐酒精提取阿片类药物。
-
10.发明授权PHARMACEUTICAL PREPARATION CONTAINING OXYCODONE AND NALOXONE 无效化学药剂ZABEREITUNG ENONALTEND OXYCODON UND NALOXON
公开(公告)号：EP1492505B1
公开(公告)日：2015-06-03
申请号：EP03720424.5
申请日：2003-04-04
申请人： EURO-CELTIQUE S.A.
IPC分类号： A61K9/16 , A61K9/20 , A61K9/22 , A61K31/485
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/70 , Y10S514/81 , Y10S514/812
摘要： The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
摘要翻译： 本发明涉及一种储存稳定的药物制剂，其优选地包含在非溶胀性扩散基质中的两种活性化合物，其中化合物以持续的不变的方式从基质中释放，并且如果存在多种化合物，则是独立的方式，并且用 相对于其基本的释放特性由乙基纤维素和至少一种脂肪醇。 本发明还涉及生产这种药物制剂的方法。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.014 秒)
